Roche to commercialize Hepatitis C drug in China with Ascletis
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.
Under the terms of the agreement, Ascletis will fund and be responsible for regulatory affairs and developing and manufacturing danoprevir in greater China, including Taiwan, Hong Kong and Macau.
Ascletis will receive payments upon reaching certain development and commercial milestones from Roche.
Ten million patients are infected annually with Hepatitis-C in China and there are no direct antiviral agents currently marketed to treat the disease, Ascletis said.
(Reporting by Caroline Copley)
- Israel says shoots down Gaza drone as calls for truce mount |
- Ukraine says Russian army officers fighting with rebels
- German database study hints diabetes drug cuts Alzheimer's risk
- Exclusive: YouTube weighs funding efforts to boost premium content - sources
- Six people injured when camera catches fire at 30 Rockefeller Plaza
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video